BNP Paribas Arbitrage SA acquired a new stake in shares of Ra Pharmaceuticals Inc (NASDAQ:RARX) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 3,917 shares of the company’s stock, valued at approximately $88,000.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Quantamental Technologies LLC acquired a new position in Ra Pharmaceuticals in the fourth quarter worth $44,000. Legal & General Group Plc boosted its holdings in shares of Ra Pharmaceuticals by 57.7% during the fourth quarter. Legal & General Group Plc now owns 3,063 shares of the company’s stock valued at $56,000 after acquiring an additional 1,121 shares during the period. Great West Life Assurance Co. Can acquired a new position in shares of Ra Pharmaceuticals during the fourth quarter valued at $63,000. Metropolitan Life Insurance Co. NY acquired a new position in shares of Ra Pharmaceuticals during the fourth quarter valued at $100,000. Finally, MetLife Investment Advisors LLC acquired a new position in shares of Ra Pharmaceuticals during the fourth quarter valued at $137,000. Institutional investors own 94.97% of the company’s stock.
Shares of NASDAQ RARX traded up $0.03 during trading hours on Wednesday, hitting $27.29. The stock had a trading volume of 422,786 shares, compared to its average volume of 429,866. The firm has a market capitalization of $1.16 billion, a P/E ratio of -13.25 and a beta of 0.80. The company has a quick ratio of 20.10, a current ratio of 20.10 and a debt-to-equity ratio of 0.02. The company’s 50-day moving average price is $22.98. Ra Pharmaceuticals Inc has a 52 week low of $8.27 and a 52 week high of $28.04.
Ra Pharmaceuticals (NASDAQ:RARX) last announced its earnings results on Thursday, May 9th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.02. Equities research analysts anticipate that Ra Pharmaceuticals Inc will post -1.98 earnings per share for the current fiscal year.
Several equities research analysts recently weighed in on the stock. Zacks Investment Research raised shares of Ra Pharmaceuticals from a “hold” rating to a “buy” rating and set a $24.00 price objective for the company in a report on Tuesday, June 11th. BidaskClub upgraded shares of Ra Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday. Jefferies Financial Group boosted their price target on shares of Ra Pharmaceuticals from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Tuesday, June 18th. Leerink Swann began coverage on shares of Ra Pharmaceuticals in a research report on Wednesday, May 22nd. They issued an “outperform” rating and a $23.30 price target on the stock. Finally, Robert W. Baird began coverage on shares of Ra Pharmaceuticals in a research report on Thursday, June 20th. They issued an “outperform” rating on the stock. One research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $37.73.
In other Ra Pharmaceuticals news, insider Alonso Ricardo sold 2,857 shares of the stock in a transaction on Friday, June 21st. The stock was sold at an average price of $23.72, for a total transaction of $67,768.04. Following the completion of the transaction, the insider now directly owns 11,428 shares in the company, valued at $271,072.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Simon Read sold 10,000 shares of the stock in a transaction on Tuesday, June 18th. The stock was sold at an average price of $22.25, for a total value of $222,500.00. Following the transaction, the insider now owns 8,521 shares of the company’s stock, valued at $189,592.25. The disclosure for this sale can be found here. 4.30% of the stock is owned by insiders.
Ra Pharmaceuticals Company Profile
Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.
Featured Article: Conference Calls and Individual Investors
Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.